Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics

Journal of Pharmaceutical Sciences

Volumn 102, Issue 11, 2013, Pages 4193-4204

  Sayama, Hiroyuki ^a   Komura, Hiroshi ^a   Kogayu, Motohiro ^a   Iwaki, Masahiro ^b  

^a JAPAN TOBACCO INC   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

ADME; in vitro in vivo extrapolation (IVIVE); Metabolic clearance; Modeling and simulation; PBPK modeling; Pharmacokinetics; Physiological model; Prediction of human pharmacokinetics; Simulations; Translational research

Indexed keywords

CAFFEINE; DIAZEPAM; DILTIAZEM; EPIROPRIM; MIDAZOLAM; NICARDIPINE; PHENAZONE; PROPAFENONE; THEOPHYLLINE; VERAPAMIL;

ACCURACY; ARTICLE; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HYBRID; NONHUMAN; RAT; SIMULATION; STEADY STATE;

ADME; IN VITRO-IN VIVO EXTRAPOLATION (IVIVE); METABOLIC CLEARANCE; MODELING AND SIMULATION; PBPK MODELING; PHARMACOKINETICS; PHYSIOLOGICAL MODEL; PREDICTION OF HUMAN PHARMACOKINETICS; SIMULATIONS; TRANSLATIONAL RESEARCH;

ANIMALS; COMPUTER SIMULATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS;

EID: 84885864833     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23726     Document Type: Article

References (28)

1. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM. 2011. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharamcol Ther 89:259-267.
2. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
3. Peters SA. 2008. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261-275.
4. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S. 2011. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharamcokinet 50:331-347.
5. Dedrick R, Bischoff KB, Zaharko DS. 1970. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
6. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, Chou RC. 1995. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285-1290.
7. Van den Bergh A, Sinha V, Gilissen R, Straetemans R, Wuyts K, Morrison D, Bijnens L, Mackie C. 2011. Prediction of human oral plasma concentration-time profiles using preclinical data: Comparative evaluation of prediction approaches in early pharmaceutical discovery. Clin Pharmacokinet 50:505-517.
8. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
9. Tang H, Mayersohn M. 2006. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95:1783-1799.
10. Sayama H, Komura H, Kogayu M. 2013. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans-usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos 41:498-507.
11. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
12. Hallifax D, Foster JA, Houston JB. 2010. Prediction of human metabolic clearance from in vitro systems: Retrospective analysis and prospective view. Pharm Res 27:2150-2161.
13. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. 2001. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
14. Jones HM, Parrott N, Jorga K, Lavé T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
15. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
16. Austin RP, Barton P, Mohmed S, Riley RJ. 2005. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425.
17. Poulin P, Theil FP. 2000. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
18. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
19. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
20. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. 2007. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35:649-659.
21. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. 2003. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
22. Gertz M, Kilford PJ, Houston JB, Galetin A. 2008. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542.
23. Fagerholm U. 2007. Prediction of human pharmacokinetics-evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 59:1181-1190.
24. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. 2007b. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780.
25. Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. 2003. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 92:1990-2007.
26. Jansson R, Bredberg U, Ashton M. 2008. Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 97:2324-2339.
27. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, Wilner KD, Koudriakova T. 2011. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: Physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 39:383-393.
28. Rostami-Hodjegan A. 2012. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: A marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50-61.